Monoclonal antibody · Kills target cells, directed at C-C chemokine receptor 8 (CCR8) · developed by Coherus Oncology
Tagmokitug is an afucosylated human IgG1 monoclonal antibody that binds CCR8 on tumor-infiltrating regulatory T-cells in the tumor microenvironment. It depletes these cells through antibody-dependent cellular cytotoxicity and phagocytosis, which may reactivate antitumor immune responses. It is being studied in metastatic and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06657144 | Phase 1 | Metastatic Solid Tumor | Recruiting | CHRS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorMetastatic Solid Tumor
See CHRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CHRS catalysts and pipeline →